Moving into the mainstream: healthcare professionals' views of implementing treatment focussed genetic testing in breast cancer care
A proportion of breast cancers are attributable to BRCA1 or BRCA2 mutations. Technological advances has meant that mutation testing in newly diagnosed cancer patients can be used to inform treatment plans. Although oncologists increasingly deliver treatment-focused genetic testing (TFGT) as part of...
| Κύριοι συγγραφείς: | , , , , , |
|---|---|
| Μορφή: | Journal article |
| Γλώσσα: | English |
| Έκδοση: |
Springer Nature
2019
|